References
- Khosla S, Riggs BL. Treatment options for osteoporosis. Mayo Clin Proc 1995; 70(10):978–82
- Riggs BL, Melton LJ 3d. The prevention and treatment of osteoporosis. N Engl J Med 1992; 327(9):620–7 [Erratum, N Engl J Med 1993; 328(1):65]
- Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117(1):1–9
- Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122(1):9–16
- Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325(11):756–62
- Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265(14):1861–7
- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273(3):199–208
- Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265(15): 1985–90 [Erratum, JAMA 1991; 266(10):1362]
- Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332(24):1589–93
- Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117(12): 1016–37
- Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156(5):1332–4
- Torgerson DJ, Donaldson C, Russell IT, et al. Hormone replacement therapy: compliance and cost after screening of osteoporosis. Eur J Obstet Gynecol Reprod Biol 1995; 59(1):57–60
- Chesnut CH 3d, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99(2):144–52
- Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333(22):1437–43
- MacIntyre I, Stevenson JC, Whitehead MI, et al. Calcitonin for prevention of postmenopausal bone loss. Lancet 1988; 1(8591):900–2
- Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98(5):452–8
- Rico H, Revilla M, Hernández ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995; 56(3):181–5
- Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305(6853):556–61
- Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992; 305(6862):1124–8
- Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322(12):802–9
- Pak CY, Sakhaee K, Adams-Huet B, et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995; 123(6):401–8